Patients with disabilities often face medical providers who make inaccurate assumptions about their quality of life that can lead to paternalism and substandard care, according to an essay published this week in the New England Journal of Medicine (NEJM).
Pfizer will end development on its experimental Duchenne muscular dystrophy gene therapy after a Phase 3 failure last month, and plans to eliminate roles at a North Carolina site that was working on the project. […]
Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced today that it has signed […]
Pfizer is launching its second-ever rebate program, this time for Panzyga, its treatment for a rare neurological disease of the peripheral nerves. The program began last month, according to STAT which first reported the news, and […]
Copyright © 2026 Biotech Networks
